Literature DB >> 20456290

The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access.

Laura Orio1, Sunmee Wee, Amy H Newman, Luigi Pulvirenti, George F Koob.   

Abstract

Previous work suggests a role for dopamine D3-like receptors in psychostimulant reinforcement. The development of new compounds acting selectively at dopamine D3 receptors has opened new possibilities to explore the role of these receptors in animal models of psychostimulant dependence. Here we investigated whether the dopamine D3 partial agonist CJB090 (1-10 mg/kg, i.v) and the D3 antagonist PG01037 (8-32 mg/kg, s.c.) modified methamphetamine (0.05 mg/kg/injection) intravenous self-administration under fixed- (FR) and progressive- (PR) ratio schedules in rats allowed limited (short access, ShA; 1-hour sessions 3 days/week) or extended access (long access, LgA; 6 hour sessions 6 days/week). Under a FR1 schedule, the highest dose of the D3 partial agonist CJB090 selectively reduced methamphetamine self-administration in LgA but not in ShA rats, whereas the full D3 antagonist PG01037 produced no effect in either group. Under a PR schedule of reinforcement, the D3 partial agonist CJB090 reduced the maximum number of responses performed ('breakpoint') for methamphetamine in LgA rats at the doses of 5 and 10 mg/kg, and also it produced a significant reduction in the ShA group at the highest dose. However, the D3 full antagonist PG01037 only reduced PR methamphetamine self-administration in LgA rats at the highest dose of 32 mg/kg with no effect in the ShA group. The results suggest that rats might be more sensitive to pharmacological modulation of dopamine D3 receptors following extended access to methamphetamine self-administration, opening the possibility that D3 receptors play a role in excessive methamphetamine intake.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20456290      PMCID: PMC2903631          DOI: 10.1111/j.1369-1600.2010.00211.x

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  80 in total

1.  The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.

Authors:  Arlene C Pak; Charles R Ashby; Christian A Heidbreder; Maria Pilla; Jeremy Gilbert; Zheng-Xiong Xi; Eliot L Gardner
Journal:  Int J Neuropsychopharmacol       Date:  2006-08-31       Impact factor: 5.176

2.  Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.

Authors:  Peter Grundt; Katherine M Prevatt; Jianjing Cao; Michelle Taylor; Christina Z Floresca; Ji-Kyung Choi; Bruce G Jenkins; Robert R Luedtke; Amy Hauck Newman
Journal:  J Med Chem       Date:  2007-08-02       Impact factor: 7.446

Review 3.  New insights into the mechanism of action of amphetamines.

Authors:  Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

4.  Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys.

Authors:  Jennifer L Martelle; Renee Claytor; Jason T Ross; Beth A Reboussin; Amy Hauck Newman; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2007-02-01       Impact factor: 4.030

5.  Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration.

Authors:  Sunmee Wee; Zhixia Wang; William L Woolverton; Luigi Pulvirenti; George F Koob
Journal:  Neuropsychopharmacology       Date:  2007-02-28       Impact factor: 7.853

Review 6.  Dopamine D3 receptor ligands for the treatment of tobacco dependence.

Authors:  Bernard Le Foll; Steven R Goldberg; Pierre Sokoloff
Journal:  Expert Opin Investig Drugs       Date:  2007-01       Impact factor: 6.206

7.  Methamphetamine blood concentrations in human abusers: application to pharmacokinetic modeling.

Authors:  William P Melega; Arthur K Cho; Dennis Harvey; Goran Laćan
Journal:  Synapse       Date:  2007-04       Impact factor: 2.562

8.  Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers.

Authors:  Ajna Hamidovic; Un Jung Kang; Harriet de Wit
Journal:  J Clin Psychopharmacol       Date:  2008-02       Impact factor: 3.153

9.  Methamphetamine self-administration and voluntary exercise have opposing effects on medial prefrontal cortex gliogenesis.

Authors:  Chitra D Mandyam; Sunmee Wee; Amelia J Eisch; Heather N Richardson; George F Koob
Journal:  J Neurosci       Date:  2007-10-17       Impact factor: 6.167

10.  1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists.

Authors:  Fabrizio Micheli; Giorgio Bonanomi; Frank E Blaney; Simone Braggio; Anna Maria Capelli; Anna Checchia; Ornella Curcuruto; Federica Damiani; Romano Di Fabio; Daniele Donati; Gabriella Gentile; Andy Gribble; Dieter Hamprecht; Giovanna Tedesco; Silvia Terreni; Luca Tarsi; Andrew Lightfoot; Geoff Stemp; Gregor Macdonald; Alex Smith; Michela Pecoraro; Marcella Petrone; Ornella Perini; Jacqui Piner; Tino Rossi; Angela Worby; Maria Pilla; Enzo Valerio; Cristiana Griffante; Manolo Mugnaini; Martyn Wood; Claire Scott; Michela Andreoli; Laurent Lacroix; Adam Schwarz; Alessandro Gozzi; Angelo Bifone; Charles R Ashby; Jim J Hagan; Christian Heidbreder
Journal:  J Med Chem       Date:  2007-09-15       Impact factor: 7.446

View more
  30 in total

1.  N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.

Authors:  Ashwini K Banala; Benjamin A Levy; Sameer S Khatri; Cheryse A Furman; Rebecca A Roof; Yogesh Mishra; Suzy A Griffin; David R Sibley; Robert R Luedtke; Amy Hauck Newman
Journal:  J Med Chem       Date:  2011-05-02       Impact factor: 7.446

2.  Investigating Methamphetamine Craving Using the Extinction-Reinstatement Model in the Rat.

Authors:  Peter R Kufahl; M Foster Olive
Journal:  J Addict Res Ther       Date:  2011-11-15

Review 3.  Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.

Authors:  Christian Heidbreder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-28       Impact factor: 3.000

Review 4.  Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction.

Authors:  Bernard Le Foll; Patricia Di Ciano
Journal:  Eur Neuropsychopharmacol       Date:  2014-09-16       Impact factor: 4.600

5.  Chronic wheel running-induced reduction of extinction and reinstatement of methamphetamine seeking in methamphetamine dependent rats is associated with reduced number of periaqueductal gray dopamine neurons.

Authors:  Jeffery C Sobieraj; Airee Kim; McKenzie J Fannon; Chitra D Mandyam
Journal:  Brain Struct Funct       Date:  2014-10-02       Impact factor: 3.270

6.  Further characterization of quinpirole-elicited yawning as a model of dopamine D3 receptor activation in male and female monkeys.

Authors:  Susan E Martelle; Susan H Nader; Paul W Czoty; William S John; Angela N Duke; Pradeep K Garg; Sudha Garg; Amy H Newman; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2014-05-29       Impact factor: 4.030

7.  Effects of Environmental Manipulations and Treatment with Bupropion and Risperidone on Choice between Methamphetamine and Food in Rhesus Monkeys.

Authors:  Matthew L Banks; Bruce E Blough
Journal:  Neuropsychopharmacology       Date:  2015-03-06       Impact factor: 7.853

8.  Increases in compulsivity, inflammation, and neural injury in HIV transgenic rats with escalated methamphetamine self-administration under extended-access conditions.

Authors:  Giordano de Guglielmo; Yu Fu; Jihuan Chen; Estefania Larrosa; Ivy Hoang; Tomoya Kawamura; Irene Lorrai; Barry Zorman; Joseph Bryant; Olivier George; Pavel Sumazin; Celine Lefebvre; Vez Repunte-Canonigo; Pietro Paolo Sanna
Journal:  Brain Res       Date:  2019-10-09       Impact factor: 3.252

9.  Brain Renin-Angiotensin System Blockade Attenuates Methamphetamine-Induced Hyperlocomotion and Neurotoxicity.

Authors:  Linhong Jiang; Ruiming Zhu; Qian Bu; Yan Li; Xue Shao; Hui Gu; Jueying Kong; Li Luo; Hailei Long; Wei Guo; Jingwei Tian; Yinglan Zhao; Xiaobo Cen
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

10.  κ Opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake.

Authors:  Timothy W Whitfield; Joel E Schlosburg; Sunmee Wee; Adam Gould; Olivier George; Yanabel Grant; Eva R Zamora-Martinez; Scott Edwards; Elena Crawford; Leandro F Vendruscolo; George F Koob
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.